Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema

Tomoko Betsuyaku, K. Takeyabu, M. Tanino, M. Nishimura

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Secretory leukocyte protease inhibitor (SLPI) is a potent inhibitor of human leukocyte elastase. In some chronic airway diseases, the level of SLPI is decreased in sputum, leading to the continuation of neutrophil inflammation. In this study, the role of SLPI in subclinical pulmonary emphysema was examined. Sequential bronchoalveolar lavage was performed in an attempt to separately evaluate the levels of SLPI in the large airways and in the peripheral airways for two groups of smokers. One group had subclinical emphysema by computed-tomography scans and one group did not. SLPI localized in alveolar macrophages (AM) was also assessed. The level of SLPI was significantly elevated in the peripheral airways from the subjects with emphysema compared to those without emphysema (1589.2±353.9 versus 729.1± 31.0 ng·mL-1), although it was similar in the large airways (3442.3±499.6 versus 2535.7± 578.8 ng·mL-1). There was a trend for higher amount of SLPI to be released from AM in subjects with subclinical emphysema, although this did not reach statistical significance. In conclusion, there is compensatory upregulation of secretory leukocyte protease inhibitor in peripheral airways in subclinical pulmonary emphysema, which is in sharp contrast to the decreased level of secretory leukocyte protease inhibitor reported in some chronic airway diseases.

Original languageEnglish
Pages (from-to)1051-1057
Number of pages7
JournalEuropean Respiratory Journal
Volume19
Issue number6
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Secretory Leukocyte Peptidase Inhibitor
Emphysema
Pulmonary Emphysema
Alveolar Macrophages
Chronic Disease
Bronchoalveolar Lavage
Sputum
Neutrophils
Up-Regulation
Tomography

Keywords

  • Alveolar macrophage
  • Bronchoalveolar lavage
  • Computed tomography
  • Pulmonary emphysema
  • Secretory leukocyte protease inhibitor

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema. / Betsuyaku, Tomoko; Takeyabu, K.; Tanino, M.; Nishimura, M.

In: European Respiratory Journal, Vol. 19, No. 6, 2002, p. 1051-1057.

Research output: Contribution to journalArticle

Betsuyaku, Tomoko ; Takeyabu, K. ; Tanino, M. ; Nishimura, M. / Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema. In: European Respiratory Journal. 2002 ; Vol. 19, No. 6. pp. 1051-1057.
@article{101e209a42924b5e9b49639ae9859cc0,
title = "Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema",
abstract = "Secretory leukocyte protease inhibitor (SLPI) is a potent inhibitor of human leukocyte elastase. In some chronic airway diseases, the level of SLPI is decreased in sputum, leading to the continuation of neutrophil inflammation. In this study, the role of SLPI in subclinical pulmonary emphysema was examined. Sequential bronchoalveolar lavage was performed in an attempt to separately evaluate the levels of SLPI in the large airways and in the peripheral airways for two groups of smokers. One group had subclinical emphysema by computed-tomography scans and one group did not. SLPI localized in alveolar macrophages (AM) was also assessed. The level of SLPI was significantly elevated in the peripheral airways from the subjects with emphysema compared to those without emphysema (1589.2±353.9 versus 729.1± 31.0 ng·mL-1), although it was similar in the large airways (3442.3±499.6 versus 2535.7± 578.8 ng·mL-1). There was a trend for higher amount of SLPI to be released from AM in subjects with subclinical emphysema, although this did not reach statistical significance. In conclusion, there is compensatory upregulation of secretory leukocyte protease inhibitor in peripheral airways in subclinical pulmonary emphysema, which is in sharp contrast to the decreased level of secretory leukocyte protease inhibitor reported in some chronic airway diseases.",
keywords = "Alveolar macrophage, Bronchoalveolar lavage, Computed tomography, Pulmonary emphysema, Secretory leukocyte protease inhibitor",
author = "Tomoko Betsuyaku and K. Takeyabu and M. Tanino and M. Nishimura",
year = "2002",
doi = "10.1183/09031936.02.00253202",
language = "English",
volume = "19",
pages = "1051--1057",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "6",

}

TY - JOUR

T1 - Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema

AU - Betsuyaku, Tomoko

AU - Takeyabu, K.

AU - Tanino, M.

AU - Nishimura, M.

PY - 2002

Y1 - 2002

N2 - Secretory leukocyte protease inhibitor (SLPI) is a potent inhibitor of human leukocyte elastase. In some chronic airway diseases, the level of SLPI is decreased in sputum, leading to the continuation of neutrophil inflammation. In this study, the role of SLPI in subclinical pulmonary emphysema was examined. Sequential bronchoalveolar lavage was performed in an attempt to separately evaluate the levels of SLPI in the large airways and in the peripheral airways for two groups of smokers. One group had subclinical emphysema by computed-tomography scans and one group did not. SLPI localized in alveolar macrophages (AM) was also assessed. The level of SLPI was significantly elevated in the peripheral airways from the subjects with emphysema compared to those without emphysema (1589.2±353.9 versus 729.1± 31.0 ng·mL-1), although it was similar in the large airways (3442.3±499.6 versus 2535.7± 578.8 ng·mL-1). There was a trend for higher amount of SLPI to be released from AM in subjects with subclinical emphysema, although this did not reach statistical significance. In conclusion, there is compensatory upregulation of secretory leukocyte protease inhibitor in peripheral airways in subclinical pulmonary emphysema, which is in sharp contrast to the decreased level of secretory leukocyte protease inhibitor reported in some chronic airway diseases.

AB - Secretory leukocyte protease inhibitor (SLPI) is a potent inhibitor of human leukocyte elastase. In some chronic airway diseases, the level of SLPI is decreased in sputum, leading to the continuation of neutrophil inflammation. In this study, the role of SLPI in subclinical pulmonary emphysema was examined. Sequential bronchoalveolar lavage was performed in an attempt to separately evaluate the levels of SLPI in the large airways and in the peripheral airways for two groups of smokers. One group had subclinical emphysema by computed-tomography scans and one group did not. SLPI localized in alveolar macrophages (AM) was also assessed. The level of SLPI was significantly elevated in the peripheral airways from the subjects with emphysema compared to those without emphysema (1589.2±353.9 versus 729.1± 31.0 ng·mL-1), although it was similar in the large airways (3442.3±499.6 versus 2535.7± 578.8 ng·mL-1). There was a trend for higher amount of SLPI to be released from AM in subjects with subclinical emphysema, although this did not reach statistical significance. In conclusion, there is compensatory upregulation of secretory leukocyte protease inhibitor in peripheral airways in subclinical pulmonary emphysema, which is in sharp contrast to the decreased level of secretory leukocyte protease inhibitor reported in some chronic airway diseases.

KW - Alveolar macrophage

KW - Bronchoalveolar lavage

KW - Computed tomography

KW - Pulmonary emphysema

KW - Secretory leukocyte protease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0035991313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035991313&partnerID=8YFLogxK

U2 - 10.1183/09031936.02.00253202

DO - 10.1183/09031936.02.00253202

M3 - Article

C2 - 12108856

AN - SCOPUS:0035991313

VL - 19

SP - 1051

EP - 1057

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 6

ER -